clinical data	cases	CD133 Positive expression (cases)	(χ2/P)	CD44 Positive expression (cases)	(χ2/P)	NLR	NLR	(χ2/P)
clinical data	cases	CD133 Positive expression (cases)	(χ2/P)	CD44 Positive expression (cases)	(χ2/P)	<2.645	≥2.645	(χ2/P)
Gender			0.205 /0.651		0.521 /0.470			1.334 /0.248
male	68	54		57		32	36
female	52	43		46		30	22
age			0.155 /0.694		1.725 /0.189			0.927 /0.336
＞60 years	67	55		60		32	35
≤60 years	53	42		43		30	23
Tumor site			1.805 /0.179		0.638 /0.424			0.008 /0.930
Peripherin	46	40		38		24	22
Central type	74	57		65		38	36
Pathological stage			7.286 /0.063		1.664 /0.645			13.661 /0.003
Phase I	14	8		11		12	2
Phase II	29	23		26		19	10
Phase III	37	30		33		17	20
Phase IV	40	36		33		14	26
Pathological type			2.933 /0.087		1.914 /0.167			0.036 /0.850
Squamous cell carcinoma	61	53		55		31	30
Adenocarcinoma	59	44		48		31	28
Degree of differentiation			11.120 /0.004		7.792 /0.020			5.570 /0.062
Hypodifferentiation	70	62		63		33	37
Mesodifferentiation	41	31		35		21	20
Highly differentiated	9	4		5		8	1
Tumor diameter			2.295 /0.130		0.411 /0.521			5.345 /0.021
＞3 cm	72	55		63		31	41
≤3 cm	48	42		40		31	17
Lymph node metastasis			6.662 /0.010		4.964 /0.026			6.509 /0.011
have	84	73		76		37	47
no	36	24		27		25	11

Table 1 : The Association between CD44, CD133, and NLR and the Pathological Characteristics of NSCLC Patients